174 related articles for article (PubMed ID: 18765274)
1. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject.
Joshi M; Pathak S; Sharma S; Patravale V
Int J Pharm; 2008 Nov; 364(1):119-26. PubMed ID: 18765274
[TBL] [Abstract][Full Text] [Related]
2. Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria.
Joshi M; Pathak S; Sharma S; Patravale V
Int J Pharm; 2008 Oct; 362(1-2):172-8. PubMed ID: 18611435
[TBL] [Abstract][Full Text] [Related]
3. Development of SMEDDS using natural lipophile: application to beta-Artemether delivery.
Mandawgade SD; Sharma S; Pathak S; Patravale VB
Int J Pharm; 2008 Oct; 362(1-2):179-83. PubMed ID: 18652886
[TBL] [Abstract][Full Text] [Related]
4. Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: Pharmacokinetics, toxicological and in vivo anti-malarial activity.
Aditya NP; Patankar S; Madhusudhan B; Murthy RS; Souto EB
Eur J Pharm Sci; 2010 Aug; 40(5):448-55. PubMed ID: 20493255
[TBL] [Abstract][Full Text] [Related]
5. Nanostructured lipid carriers of artemether-lumefantrine combination for intravenous therapy of cerebral malaria.
Prabhu P; Suryavanshi S; Pathak S; Patra A; Sharma S; Patravale V
Int J Pharm; 2016 Nov; 513(1-2):504-517. PubMed ID: 27596113
[TBL] [Abstract][Full Text] [Related]
6. Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity.
Parashar D; Aditya NP; Murthy RS
Drug Deliv; 2016; 23(1):123-9. PubMed ID: 24786480
[TBL] [Abstract][Full Text] [Related]
7. Intravenous β-artemether formulation (ARM NLC) as a superior alternative to commercial artesunate formulation.
Patil S; Joshi M; Pathak S; Sharma S; Patravale V
J Antimicrob Chemother; 2012 Nov; 67(11):2713-6. PubMed ID: 22899802
[TBL] [Abstract][Full Text] [Related]
8. Formulation design and in vivo antimalarial evaluation of lipid-based drug delivery systems for oral delivery of β-arteether.
Memvanga PB; Préat V
Eur J Pharm Biopharm; 2012 Sep; 82(1):112-9. PubMed ID: 22609572
[TBL] [Abstract][Full Text] [Related]
9. Artemether-lumefantrine nanostructured lipid carriers for oral malaria therapy: Enhanced efficacy at reduced dose and dosing frequency.
Prabhu P; Suryavanshi S; Pathak S; Sharma S; Patravale V
Int J Pharm; 2016 Sep; 511(1):473-487. PubMed ID: 27421912
[TBL] [Abstract][Full Text] [Related]
10. Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance.
Nnamani PO; Ugwu AA; Ibezim EC; Kenechukwu FC; Akpa PA; Ogbonna JN; Obitte NC; Odo AN; Windbergs M; Lehr CM; Attama AA
Int J Nanomedicine; 2016; 11():6365-6378. PubMed ID: 27932882
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of novel lipid based formulation of β-Artemether and Lumefantrine in murine malaria model.
Patil S; Suryavanshi S; Pathak S; Sharma S; Patravale V
Int J Pharm; 2013 Oct; 455(1-2):229-34. PubMed ID: 23886650
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion.
Huang ZR; Hua SC; Yang YL; Fang JY
Acta Pharmacol Sin; 2008 Sep; 29(9):1094-102. PubMed ID: 18718178
[TBL] [Abstract][Full Text] [Related]
13. Development of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application.
Nnamani PO; Hansen S; Windbergs M; Lehr CM
Int J Pharm; 2014 Dec; 477(1-2):208-17. PubMed ID: 25290810
[TBL] [Abstract][Full Text] [Related]
14. Ameliorating the in vivo antimalarial efficacy of artemether using nanostructured lipid carriers.
Vanka R; Kuppusamy G; Praveen Kumar S; Baruah UK; Karri VVSR; Pandey V; Babu PP
J Microencapsul; 2018 Mar; 35(2):121-136. PubMed ID: 29448884
[TBL] [Abstract][Full Text] [Related]
15. Artemisinin and artemisinin plus curcumin liposomal formulations: enhanced antimalarial efficacy against Plasmodium berghei-infected mice.
Isacchi B; Bergonzi MC; Grazioso M; Righeschi C; Pietretti A; Severini C; Bilia AR
Eur J Pharm Biopharm; 2012 Apr; 80(3):528-34. PubMed ID: 22142592
[TBL] [Abstract][Full Text] [Related]
16. Optimization of artemether-loaded NLC for intranasal delivery using central composite design.
Jain K; Sood S; Gowthamarajan K
Drug Deliv; 2015; 22(7):940-54. PubMed ID: 24512368
[TBL] [Abstract][Full Text] [Related]
17. Nanoencapsulation increases quinine antimalarial efficacy against Plasmodium berghei in vivo.
Haas SE; Bettoni CC; de Oliveira LK; Guterres SS; Dalla Costa T
Int J Antimicrob Agents; 2009 Aug; 34(2):156-61. PubMed ID: 19369041
[TBL] [Abstract][Full Text] [Related]
18. Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration.
Akpa PA; Ugwuoke JA; Attama AA; Ugwu CN; Ezeibe EN; Momoh MA; Echezona AC; Kenechukwu FC
Afr Health Sci; 2020 Dec; 20(4):1679-1697. PubMed ID: 34394228
[TBL] [Abstract][Full Text] [Related]
19. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies.
Jia L; Zhang D; Li Z; Duan C; Wang Y; Feng F; Wang F; Liu Y; Zhang Q
Colloids Surf B Biointerfaces; 2010 Oct; 80(2):213-8. PubMed ID: 20621458
[TBL] [Abstract][Full Text] [Related]
20. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)--effects of formulation parameters on physicochemical stability.
Teeranachaideekul V; Müller RH; Junyaprasert VB
Int J Pharm; 2007 Aug; 340(1-2):198-206. PubMed ID: 17482778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
